×

Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

  • US 10,363,255 B2
  • Filed: 01/25/2018
  • Issued: 07/30/2019
  • Est. Priority Date: 08/08/2014
  • Status: Active Grant
First Claim
Patent Images

1. A pharmaceutical solution comprising:

  • (i) β

    -cyclodextrin sulfobutyl ether, hydroxypropyl β

    -cyclodextrin, or a combination thereof;

    (ii) about 0.2% to about 1.0% of polyvinylpyrrolidone; and

    (iii) about 30 mg/mL to about 60 mg/mL of an ophthalmic therapeutic agent having a solubility of less than 1 mg/mL in water;

    wherein the weight ratio of (i) to (iii) is from about 2;

    1 to about 8;

    1.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×